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Abstract
Biomarkers unrelated to myocardial necrosis, such as cystatin C, copeptin, and mid-
regional pro-adrenomedullin (MR-proADM), showed promise for cardiovascular risk pre-
diction. Knowing whether they are comparable to cardiac biomarkers such as high-sensi-
tive cardiac-troponin T (hs-cTnT) or N-terminal pro-Brain natriuretic peptide (NT-proBNP)
in elderly patients with acute non-massive pulmonary embolism (NMPE) remains elusive.
This study aims at comparing the prognostic accuracy of cardiac and non-cardiac bio-
markers in patients with NMPE aged65 years over time. In the context of the
SWITCO65+ cohort, we evaluated 227 elderly patients with an available blood sample
taken within one day from diagnosis. The primary study endpoint was defined as PE-
related mortality and the secondary endpoint as PE-related complications. The biomark-
ers’ predictive ability at 1, 3, 12 and 24 months was determined using C-statistics and Cox
regression. For both study endpoints, C-statistics (95% confidence interval) were stable
over time for all biomarkers, with the highest value for hs-cTnT, ranging between 0.84
(0.68–1.00) and 0.80 (0.70–0.90) for the primary endpoint, and between 0.74 (0.63–0.86)
and 0.65 (0.57–0.73) for the secondary endpoint. For both study endpoints, cardiac bio-
markers were found to be independently associated with risk, NT-proBNP displaying a
negative predictive value of 100%. Among non-cardiac biomarkers, only copeptin and
MR-proADM were independent predictors of PE-related mortality but they were not inde-
pendent predictors of PE-related complications, and displayed lower negative predictive
values. In elderly NMPE patients, cardiac biomarkers appear to be valuable prognostic to
identify very low-risk individuals.
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Introduction
An important aspect of risk stratification in patients suffering from non-massive pulmonary
embolism (PE) is the timely identification of very low risk patients who could safely be eligible
for outpatient treatment. [1–5]. To achieve this goal, different prognostic algorithms have been
developed and rely either on clinically based scores or on biomarkers [1, 6]. Among the latter,
the most extensively studied biomarkers are cardiac biomarkers reflecting either cardiac myo-
cyte stretch, such as B type natriuretic peptides (BNP), or necrosis, such as cardiac troponins
(cTn) [6–10], which may provide independent and incremental value over clinical prediction
rules in the elderly population [9]. Nevertheless, there is a growing body of evidence indicating
that non-cardiac biomarkers, including markers of kidney failure (Cystatin C) or markers of
endogenous stress, such as copeptin, the C-terminal fragment of arginin-vasopressin, and mid-
regional proadrenomedullin (MR-proADM), could be of interest to identify individuals at risk
of death with different acute diseases, including PE patients [11–15]. Nevertheless, how these
non-cardiac biomarkers would perform in comparison to cardiac biomarkers has never been
studied.
In this “head-to-head” comparison, we aimed to i) compare the prognostic accuracies of
non-cardiac biomarkers (cystatin C, ultra-sensitive copeptin, and MR-proADM) versus cardiac
biomarkers (high sensitive cTnT (hs-cTnT) and N-terminal proBNP (NT-proBNP)), and ii)
determine the evolution of their respective prognostic accuracies over time in patients with
non-massive PE aged 65 years or older.
Methods
Patient population and study design
This study is an ancillary study of the SWITCO65+ study, a prospective multicenter cohort
dedicated to assess long-term prognosis of patients65 years with proven deep vein thrombo-
sis or PE in five university and four high-volume non-university hospitals in Switzerland [9,
16]. All patients provided written informed consent before enrolment and all local research
ethics committees (“Comité d’Ethique des Départements de Médecine Interne et Médecine
Communautaire et de Premier Recours”) approved the study and the consent procedure. The
detailed study methods were previously published [17].
In total, the main study enrolled 695 patients with acute PE between September 2009 and
March 2012. PE diagnosis was defined as a positive spiral CT or pulmonary angiography, a
high probability on ventilation perfusion scintigraphy, or a proximal deep venous thrombosis
(DVT) documented on compression ultrasonography or angiography [16]. Briefly, exclusion
criteria included catheter-related thrombosis, insufficient German or French speaking ability,
conditions incompatible with follow-up (i.e. terminal illness), an inability to provide informed
consent (i.e severe dementia) and previous enrolment in the cohort.
For this ancillary study, patients with massive PE, defined by a systolic pressure 90
mmHg according to the European Society of Cardiology guidelines [1], were excluded (10
patients), as well as patients withdrawing consent within one day from inclusion or denying
use of data (8 patients) and PE patients with no blood sample or for which blood samples were
taken more than one day after diagnosis (450 patients), leaving 227 patients eligible for this
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analysis. Baseline demographic characteristics and clinical data were prospectively collected by
medical records review performed by trained research nurses.
Patients' follow-up
All patients completed follow-up at one, three, twelve, and twenty-four months after enrol-
ment. Follow-up included one telephone interview and two surveillance face-to-face evalua-
tions during the first year of study participation and then semi-annual contacts, alternating
between face-to-face evaluations (clinic visits or home visits in house-bound patients) and tele-
phone calls as well as periodic reviews of the patient’s hospital chart. During each visit/contact,
study nurses interviewed patients to obtain information about the date, type, and circum-
stances (i.e., following a fall) of bleeding episodes and VTE recurrences, and assessed whether
the patient had died. If a clinical event had occurred, this information was complemented by
reviewing medical charts and interviewing patients’ primary care physicians and/or family
members who provided written informed consent.
Definition of endpoints
Two predetermined endpoints were used for this study. The primary endpoint consisted in
PE-related mortality defined as all deaths definitely or possibly related to PE, as previously
described [9, 16, 17]. The secondary composite endpoint consisted in PE-related complications
defined by the following outcomes: PE-related death, recurrence of venous thromboembolic
events (VTE) or major bleeding, as previously reported [9, 16, 17].
All study endpoints were adjudicated based on the consensus of three clinical experts who
were blinded to patient characteristics and biochemical results. Diagnosis of VTE during fol-
low-up was established according to the usual criteria: for deep venous thrombosis on the basis
of abnormal results on ultrasonography; for pulmonary embolism on the basis of ventilation-
perfusion lung scan showing a high-probability pattern, CT or angiography showing intralum-
inal defects, or confirmation of a new PE on autopsy [16].
Sample Collection
Venous blood samples were collected at the respective emergency departments of recruiting
centres, within one day of the diagnosis. Samples were immediately centrifuged, frozen and
stored at– 80°C until analyses. Details regarding blood sampling/processing were described
elsewhere [18].
Biochemical Analyses
All samples were sent for analyses to the Geneva University Hospitals in order to avoid bias
related to analytical differences. Plasma concentrations of Cystatin C were measured on an
Image™ immunonephelometer (Beckmann Coulter Brea, Ca, USA) using Dako Cystatin C
reagents (Dako, Glostrup, Denmark). Copeptin and MR-proADM, were measured with a
KRYPTOR™ system using immunoassays based upon time-resolved fluorescence technology
(Thermo Scientific, BRAHMS AG, Hennigsdorf/Berlin, Germany). As no validated cut-offs
exist for non-cardiac biomarkers in the context of risk stratification for PE, we used retrospec-
tively determined cut-offs, as described in the statistical analysis section.
NT-proBNP and hs-cTnT were measured by electrochemiluminescence methods on Cobas
e601 analysers (Elecsys™, Roche, Rotkreuz, Switzerland). For hs-cTnT, we used a cut-off of 14
ng/L corresponding to the value above the 99th percentile of our healthy population with a
coefficient of variation of 10% as recommended and endorsed by the third universal definition
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of myocardial infarction [19–20]. For NT-proBNP, we prospectively used the cut-off of 300
pg/ml validated for heart failure exclusion regardless of age and gender [21], which has also
been reported to display negative predictive values above 98% for PE-related complications at
different follow-up durations in all coming or elderly patients with non-massive PE [9–10].
Statistical analysis
We estimated the cumulative incidence of outcomes for categories of biomarker levels using
the Kaplan-Meier technique. For NT-proBNP and hs-cTNT, we used the prospectively defined
and validated cut–offs of 300 pg/mL and 14 ng/L respectively [9–10]. As we aimed to focus on
the negative predictive value of the biomarkers for both primary and secondary outcome, we
arbitrarily set the cut-off for the non-cardiac biomarkers at the values corresponding to the
20th percentile. We assessed associations between log-transformed biomarker values and the
outcomes using Cox-regression. Results were reported as unadjusted and adjusted hazard
ratios (HR) with corresponding 95% confidence intervals (CIs) and p-values. HRs were
adjusted for the PESI score [2] concerning PE-related mortality and for the Geneva prognostic
score (GPS) [22] for PE-related complications. For the calculation of the PESI and GPS, we
assumed comorbidities and conditions as absent or normal if information was missing. The
discriminative ability of the biomarkers for events at 1 month, 3 months, 12 months, and 24
months was assessed by the sensitivity, specificity, positive and negative predictive value, and
Harrell’s C-statistic, which is equivalent to the area under the ROC curve (AUC) in the case of
binary outcomes. All analyses were done using Stata 13 (Stata Corporation, College Station,
Texas, USA).
Results
Patients’ baseline characteristics
Patients’ demographic characteristics and median biomarker values upon admission are listed
in Table 1. Given the high exclusion rate (65%) due to the absence of blood sample or to blood
sampling performed more than 1 day after diagnosis, we examined whether difference in
patients’ baseline characteristic could be observed between analysed (n = 227) and non-ana-
lysed patients (n = 450). Body mass index and the proportion of female gender and patients
with blood oxygen saturation below 90% were found to be significantly lower in the analysed
patients group than in the non-analysed patients group. All other patient characteristics were
comparable between the two groups (data not shown).
Incidence of endpoint according to follow-up duration
The primary endpoint was met by 2.6% (6/227) of patients at 1 month, 4.0% (9/227) at 3
months, 5.3% (12/227) at 12 months and 5.7% (13/227) at 24 months. Almost 9% (20/227) of
patients experienced PE-related complications at 1 month, 11.0% (25/227) at 3 months, 18.9%
(43/227) at 12 months, and 24.2% (55/227) at 24 months. The number of events according to
different follow-up durations is summarized in Table 2.
Non-cardiac and cardiac biomarkers values upon admission and their
association with study endpoints
With the exception of cystatin C that showed no discrimination at any time during the follow-
up, C-statistics reported below indicated that all other biomarkers displayed a significant dis-
criminative power for the primary endpoint (Table 3).
Cardiac and Non-Cardiac Biomarkers SWITCO65+cohort
PLOS ONE | DOI:10.1371/journal.pone.0155973 May 24, 2016 4 / 14
Table 1. Patients baseline characteristics.
Characteristic % (n) or median (IQR)
n = 227
Age, years 75 (69–81)
Female gender 41.4% (94)
DVT (any) 19.8% (45)
Proximal DVT 17.6% (40)
Systolic Blood pressure <100 mm Hg 1.8% (4)
Pulse rate 110 beats/min. 11.9% (27)
Respiratory rate 30 breaths/min. 4.0% (9)
Oxygen saturation <90% 9.7% (22)
Temperature <36°C 7.9% (18)
BMI (kg/m2) 27 (24–30)
Altered mental status 2.6% (6)
Diabetes mellitus 15.4% (35)
History of coronary heart disease 17.6% (40)
Heart failure† 10.1% (23)
Arterial hypertension 65.2% (148)
Cerebrovascular disease‡ 8.8% (20)
Chronic lung disease¶ 14.5% (33)
Chronic renal disease†† 16.3% (37)
Smoker (current or past) 50.2% (114)
Estrogen therapy during the last 3 months 2.2% (5)
Immobilization during the last 3 months§ 22.5% (51)
Major surgery during the last 3 months 14.5% (33)
History of VTE 30.0% (68)
History of DVT 17.6% (40)
Active cancer# 17.2% (39)
Cystatin C (mg/L) 0.99 (0.85–1.23)
Cystatin C > 20th percentile (> 0.83 mg/L) 79.3% (180)
Copeptin (pmol/L) 11 (5–22)
Copeptin >20th percentile (> 4.66 pmol/L) 79.7% (181)
MR-ProADM (nmol/L) 0.90 (0.68–1.19)
MR-ProADM >20th percentile (> 0.66 nmol/L) 79.7% (181)
hs cTnT (ng/L) 17 (8–34)
hs cTnT >14 ng/L 57.3% (130)
NT-proBNP (pg/mL) 658 (229–2233)
NT-proBNP >300 pg/mL 68.7% (156)
Data were missing for respiratory rate (18%), oxygen (6%), temperature (2%), BMI (0.4%), smoking status
(0.4%), and estrogen therapy (0.4%).
†Acute heart failure NYHA class II/IV during the last 3 months, known history of systolic or diastolic heart
failure, left or right heart failure, forward or backward heart failure, or a known left ventricular ejection
fraction of <40%.
‡History of ischemic or hemorrhagic stroke or a transient ischemic attack.
¶Chronic obstructive pulmonary disease, active asthma, lung ﬁbrosis, cystic ﬁbrosis, or bronchiectasies.
††Diabetic or hypertensive nephropathy, chronic glomerulonephritis, chronic interstitial nephritis, myeloma-
related nephropathy, or cystic kidney disease.
§Fracture or cast of the lower extremity, bed rest >72 hours, or voyage in sitting position for >6 hours during
the last 3 months
#Cancer (solid or hematologic) requiring surgery, chemotherapy, radiotherapy, or palliative care during the
last 3 months.
Abbreviations:
DVT: deep venous thrombosis
BMI: body mass index
doi:10.1371/journal.pone.0155973.t001
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Table 2. Cumulative number and proportion of events according to follow-up duration.
at 1 month % (n) at 3 months* % (n) at 12 months* % (n) at 24 months* % (n)
Primary Endpoint
PE-related mortality 2.6 (6) 4.0 (9) 5.3 (12) 5.7 (13)
Secondary Endpoint
PE-related complications: 8.8 (20) 11.0 (25) 18.9 (43) 24.2 (55)
PE-related mortality 2.6 (6) 4.0 (9) 5.3 (12) 5.7 (13)
VTE recurrence 0.9 (2) 2.6 (6) 7.9 (18) 10.1 (23)
Major bleeding 6.2 (14) 7.0 (16) 10.6 (24) 13.7 (31)
* from baseline
doi:10.1371/journal.pone.0155973.t002
Table 3. Evolution of sensitivity, specificity and predictive values over time.
PE-related mortality
C-statistics*
(95% CI)
Speciﬁcity
(95% CI)
Sensitivity
(95% CI)
Positive predictive value
(95% CI)
Negative predictive value
(95% CI)
1 month
NT-proBNP1 0.82 (0.66–0.97) 32.1 (26.3–38.5) 100.0 (61.0–100.0) 3.8 (1.8–8.1) 100.0 (94.9–100.0)
hs-cTnT2 0.84 (0.68–1.00) 43.4 (37.1–50.0) 83.3 (43.6–97.0) 3.8 (1.7–8.7) 99.0 (94.4–99.8)
Copeptin3 0.75 (0.52–0.98) 20.4 (15.6–26.2) 83.3 (43.6–97.0) 2.8 (1.2–6.3) 97.8 (88.7–99.6)
MR-
proADM3
0.75 (0.49–1.00) 20.4 (15.6–26.2) 83.3 (43.6–97.0) 2.8 (1.2–6.3) 97.8 (88.7–99.6)
Cystatin C3 0.48 (0.16–0.81) 19.9 (15.2–25.7) 50.0 (18.8–81.2) 1.7 (0.6–4.8) 93.6 (82.8–97.8)
3 months
NT-proBNP1 0.83 (0.70–0.95) 32.6 (26.7–39.0) 100.0 (70.1–100.0) 5.8 (3.1–10.6) 100.0 (94.9–100.0)
hs-cTnT2 0.83 (0.70–0.95) 44.0 (37.6–50.7) 88.9 (56.5–98.0) 6.2 (3.2–11.7) 99.0 (94.4–99.8)
Copeptin3 0.79 (0.60–0.97) 20.6 (15.8–26.5) 88.9 (56.5–98.0) 4.4 (2.3–8.5) 97.8 (88.7–99.6)
MR-
proADM3
0.80 (0.60–1.00) 20.6 (15.8–26.5) 88.9 (56.5–98.0) 4.4 (2.3–8.5) 97.8 (88.7–99.6)
Cystatin C3 0.54 (0.28–0.79) 20.2 (15.4–26.0) 66.7 (35.4–87.9) 3.3 (1.5–7.1) 93.6 (82.8–97.8)
12 months
NT-proBNP1 0.80 (0.69–0.91) 33.0 (27.1–39.6) 100.0 (75.7–100.0) 7.7 (4.5–13.0) 100.0 (94.9–100.0)
hs-cTnT2 0.81 (0.70–0.92) 44.2 (37.7–50.9) 83.3 (55.2–95.3) 7.7 (4.2–13.6) 97.9 (92.8–99.4)
Copeptin3 0.79 (0.66–0.92) 20.9 (16.0–26.9) 91.7 (64.6–98.5) 6.1 (3.4–10.6) 97.8 (88.7–99.6)
MR-
proADM3
0.83 (0.68–0.97) 20.9 (16.0–26.9) 91.7 (64.6–98.5) 6.1 (3.4–10.6) 97.8 (88.7–99.6)
Cystatin C3 0.58 (0.39–0.78) 20.5 (15.6–26.4) 75.0 (46.8–91.1) 5.0 (2.7–9.2) 93.6 (82.8–97.8)
24 months
NT-proBNP1 0.81 (0.71–0.91) 33.2 (27.2–39.7) 100.0 (77.2–100.0) 8.3 (4.9–13.7) 100.0 (94.9–100.0)
hs-cTnT2 0.80 (0.70–0.90) 44.4 (37.9–51.1) 84.6 (57.8–95.7) 8.5 (4.8–14.5) 97.9 (92.8–99.4)
Copeptin3 0.79 (0.67–0.92) 21.0 (16.1–27.0) 92.3 (66.7–98.6) 6.6 (3.8–11.2) 97.8 (88.7–99.6)
MR-
proADM3
0.84 (0.70–0.97) 21.0 (16.1–27.0) 92.3 (66.7–98.6) 6.6 (3.8–11.2) 97.8 (88.7–99.6)
Cystatin C3 0.61 (0.42–0.79) 20.6 (15.7–26.5) 76.9 (49.7–91.8) 5.6 (3.0–9.9) 93.6 (82.8–97.8)
*For calculating the c-statistics, biomarker values were used continuous.
1 for values > 300 pg/ml
2 for values > 14 ng/L
3 for values > 20th percentile
doi:10.1371/journal.pone.0155973.t003
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Risk prediction according to cardiac biomarkers
Regarding the primary endpoint, C-statistics for cardiac biomarkers ranged between 0.80 and
0.84 and tended to remain stable during the 24-month observation period. More precisely,
NT-proBNP had a C-statistic of 0.82 (95% CI: 0.66–0.97) and 0.81 (95% CI: 0.71–0.91) after 1
month and 24 months, respectively. hs-cTnT had a C-statistic of 0.84 (95% CI: 0.68–1.00) and
0.80 (95% CI: 0.70–0.90) at 1 and 24 months, respectively (Table 3).
Cox regression analyses indicated that NT-proBNP was associated with a two-fold increased
risk of PE-related mortality (HR: 2.46 per log-unit increase, 95% CI: 1.26–4.80) that remained
stable after adjustment for the PESI score (HR: 2.30, 95% CI: 1.16–4.53). This two-fold increase
in risk appeared to be stable over time with HRs of 2.30 (95% CI: 1.49–3.55) and 2.15 (95% CI:
1.38 to 3.36) for unadjusted and adjusted analyses, respectively, after a follow-up of two years
(Table 4).
At 30 days, hs-cTnT was also associated with increased risk of PE-related mortality (HR: 1.59
per log-unit increase, 95% CI: 1.17–2.16), which remained unchanged after PESI-adjustment
Table 4. Association of biomarkers with outcomes.
PE-related mortality
Crude HR (95% CI) p-value Adjusted HR* (95% CI) p-value
1 month
NT-proBNP1 2.46 (1.26 to 4.80) 0.008 2.30 (1.16 to 4.53) 0.02
hs-cTnT2 1.59 (1.17 to 2.16) 0.003 1.59 (1.16 to 2.16) 0.004
Copeptin3 2.39 (1.06 to 5.36) 0.04 2.15 (0.97 to 4.80) 0.06
MR-proADM3 3.54 (1.11 to 11.28) 0.03 3.13 (0.93 to 10.56) 0.07
Cystatin C3 0.67 (0.05 to 9.15) 0.76 0.43 (0.02 to 7.61) 0.56
3 months
NT-proBNP1 2.64 (1.51 to 4.61) <0.001 2.49 (1.41 to 4.41) 0.002
hs-cTnT2 1.56 (1.20 to 2.02) <0.001 1.56 (1.19 to 2.05) 0.001
Copeptin3 2.87 (1.44 to 5.74) 0.003 2.62 (1.32 to 5.23) 0.006
MR-proADM3 4.51 (1.85 to 10.98) <0.001 4.10 (1.63 to 10.29) 0.003
Cystatin C3 1.11 (0.16 to 7.75) 0.91 0.80 (0.10 to 6.75) 0.84
12 months
NT-proBNP1 2.18 (1.40 to 3.40) <0.001 2.04 (1.30 to 3.22) 0.002
hs-cTnT2 1.50 (1.18 to 1.90) 0.001 1.51 (1.17 to 1.93) 0.001
Copeptin3 2.99 (1.62 to 5.52) <0.001 2.76 (1.50 to 5.07) 0.001
MR-proADM3 5.01 (2.36 to 10.64) <0.001 4.60 (2.12 to 9.97) <0.001
Cystatin C3 1.70 (0.37 to 7.69) 0.49 1.33 (0.26 to 6.85) 0.73
24 months
NT-proBNP1 2.30 (1.49 to 3.55) <0.001 2.15 (1.38 to 3.36) <0.001
hs-cTnT2 1.48 (1.17 to 1.87) 0.001 1.49 (1.16 to 1.90) 0.002
Copeptin3 2.99 (1.65 to 5.40) <0.001 2.76 (1.53 to 4.97) <0.001
MR-proADM3 5.26 (2.57 to 10.75) <0.001 4.84 (2.32 to 10.10) <0.001
Cystatin C3 2.59 (0.74 to 9.05) 0.14 2.15 (0.57 to 8.19) 0.26
Biomarkers were log-transformed and used continuous. Effects (HRs) are expressed per one log-unit increase.
* adjusted for PESI
1 for values > 300 pg/ml
2 for values > 14 ng/L
3 for values > 20th percentile
doi:10.1371/journal.pone.0155973.t004
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(HR: 1.59, 95% CI: 1.16–2.16). Similar to NT-proBNP, the risk appeared to be stable during the
whole follow-up period (HR of 1.48 (95% CI: 1.17–1.87) and 1.49 (95% CI: 1.16–1.90) for unad-
justed and adjusted analyses, respectively, after two years). Cardiac biomarkers were indepen-
dently associated with PE-related mortality at any time.
Kaplan-Meier curves showed that patients with NT-proBNP and hs-cTnT values above the
pre-specified cut-off had a significantly higher cumulative incidence of PE-related death after
24 months than patients with values below the cut-off (9% vs 0% for NT-proBNP and 9% vs
2% for hs-cTnT, Fig 1).
Table 3 summarizes the evolution of cardiac biomarkers’ specificities, sensitivities and pre-
dictive values over time for the primary endpoint. At the pre-specified cut-off for NT-proBNP
(300 pg/ml) and hs-cTnT (14 ng/L), negative predictive values remained over 100% (95% CI:
94.9–100) and 97.9% (95% CI: 92.8–99.4), respectively, for PE-related mortality during the
whole follow-up. Table 3 also summarizes the evolution of non-cardiac biomarkers’ specifici-
ties, sensitivities and predictive values over time for PE-related death. Among non-cardiac
biomarkers, copeptin and MR-proADM displayed highest negative predictive values, both
reaching 97.8% (95% CI: 88.7–99.6) at 3, 12, and 24 months of follow-up.
Regarding the secondary endpoint, C-statistics for cardiac biomarkers ranged between 0.63
and 0.74 and were stable up to 3 months before decreasing gradually. For NT-proBNP, C-sta-
tistic evolved from 0.68 (95% CI: 0.57–0.78) after 1 month to 0.63 (95% CI: 0.56–0.70) after 24
months, while hs-cTnT values were 0.74 (95% CI: 0.63–0.86) after 1 month and 0.65 (95% CI:
0.57–0.73) after 24 months (Table 5).
Cox regression analyses indicated that NT-proBNP and hs-cTnT were associated with an
increased risk of 30-days complications by a factor of around 1.5 for a one log-unit increase
(HR: 1.45, 95% CI: 1.07–1.96 for NT-proBNP, and 1.48, 95% CI: 1.22–1.80 for hs-cTnT),
which remained stable after adjustment for GPS score (HR: 1.35, 95% CI: 0.99–1.85 for NT-
proBNP and HR: 1.56, 95% CI: 1.26–1.92 for hs-cTnT). After two years, NT-proBNP and hs-
cTnT levels were associated with a significant and similar risk of complications (HR: 1.31, 95%
CI: 1.10–1.56 and 1.26, 95% CI: 1.08–1.46, respectively), which remained stable after GPS score
adjustment (HR: 1.30, 95% CI: 1.08–1.56 for NT-proBNP and HR: 1.27, 95% CI: 1.09–1.48 for
hs-cTnT). Except for NT-proBNP at 30 days of follow-up, cardiac biomarkers were indepen-
dently associated with PE-related complications (Table 6).
For the secondary endpoint, Kaplan-Meier curves showed that only patients with NT-
proBNP values above the pre-specified cut-off had a significantly higher cumulative incidence
of event at 24 months than patients with values below the cut-off (32% vs 16%), whereas no sig-
nificant difference was observed for hs-cTnT (31% vs 22%, Fig 2).
Fig 1. Cumulative incidence of PE-relatedmortality by level of NT-proBNP (left panel) and hs-cTnT
(right panel).High versus low levels are based on pre-specified cut-offs (>300 pg/mL for NT-proBNP and
>14 ng/L for hs-cTnT).
doi:10.1371/journal.pone.0155973.g001
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Table 5 summarizes the evolution of cardiac biomarkers’ specificities, sensitivities and pre-
dictive values over time for the secondary endpoint. At the pre-specified cut-offs for NT-
proBNP (300 pg/ml) and hs-cTnT (14 ng/L), negative predictive values for PE-related compli-
cations were 98.6% (95% CI: 92.4–99.8) and 95.9% (95% CI: 89.9–98.4), respectively, up to 30
days and remained over 85.9% (95% CI: 76.0–92.2) and 80.4% (95% CI: 71.4–87.1) during the
2-year follow-up.
Risk prediction according to non-cardiac biomarkers
Regarding the primary endpoint, non-cardiac biomarkers had lower C-statistic values than car-
diac biomarkers. The C-statistic of non-cardiac biomarkers tended to increase over time. Fur-
thermore, only copeptin showed a significant discriminative power at all times during the
Table 5. Evolution of sensitivity, specificity and predictive values over time.
PE-related complications
C-statistics*
(95% CI)
Speciﬁcity
(95% CI)
Sensitivity
(95% CI)
Positive predictive value
(95% CI)
Negative predictive value
(95% CI)
1 month
NT-proBNP1 0.68 (0.57–0.78) 33.8 (27.7–40.5) 95.0 (76.4–99.1) 12.2 (7.9–18.2) 98.6 (92.4–99.8)
hs-cTnT2 0.74 (0.63–0.86) 44.9 (38.3–51.7) 80.0 (58.4–91.9) 12.3 (7.7–19.1) 95.9 (89.9–98.4)
Copeptin3 0.60 (0.46–0.73) 20.8 (15.8–26.8) 85.0 (64.0–94.8) 9.4 (5.9–14.5) 93.5 (82.5–97.8)
MR-
proADM3
0.60 (0.45–0.75) 20.3 (15.4–26.3) 80.0 (58.4–91.9) 8.8 (5.5–13.9) 91.3 (79.7–96.6)
Cystatin C3 0.47 (0.33–0.62) 19.3 (14.5–25.2) 65.0 (43.3–81.9) 7.2 (4.3–12.0) 85.1 (72.3–92.6)
3 months
NT-proBNP1 0.68 (0.57–0.78) 34.2 (28.0–40.9) 92.0 (75.0–97.8) 14.7 (10.0–21.2) 97.2 (90.3–99.2)
hs-cTnT2 0.73 (0.62–0.84) 45.5 (38.8–52.4) 80.0 (60.9–91.1) 15.4 (10.2–22.6) 94.8 (88.5–97.8)
Copeptin3 0.64 (0.52–0.76) 21.3 (16.2–27.4) 88.0 (70.0–95.8) 12.2 (8.2–17.7) 93.5 (82.5–97.8)
MR-
proADM3
0.62 (0.48–0.76) 20.3 (15.3–26.4) 80.0 (60.9–91.1) 11.0 (7.3–16.5) 89.1 (77.0–95.3)
Cystatin C3 0.50 (0.37–0.63) 19.8 (14.9–25.8) 72.0 (52.4–85.7) 10.0 (6.4–15.3) 85.1 (72.3–92.6)
12 months
NT-proBNP1 0.65 (0.57–0.73) 35.9 (29.3–43.0) 88.4 (75.5–94.9) 24.4 (18.3–31.7) 93.0 (84.6–97.0)
hs-cTnT2 0.69 (0.60–0.77) 46.2 (39.1–53.4) 72.1 (57.3–83.3) 23.8 (17.3–31.9) 87.6 (79.6–92.8)
Copeptin3 0.60 (0.51–0.69) 21.2 (15.9–27.7) 83.7 (70.0–91.9) 19.9 (14.7–26.3) 84.8 (71.8–92.4)
MR-
proADM3
0.59 (0.49–0.69) 20.7 (15.4–27.1) 81.4 (67.4–90.3) 19.3 (14.2–25.7) 82.6 (69.3–90.9)
Cystatin C3 0.49 (0.40–0.59) 18.5 (13.5–24.7) 69.8 (54.9–81.4) 16.7 (11.9–22.8) 72.3 (58.2–83.1)
24 months
NT-proBNP1 0.63 (0.56–0.70) 35.5 (28.7–42.9) 81.8 (69.7–89.8) 28.8 (22.3–36.4) 85.9 (76.0–92.2)
hs-cTnT2 0.65 (0.57–0.73) 45.3 (38.1–52.8) 65.5 (52.3–76.6) 27.7 (20.7–35.9) 80.4 (71.4–87.1)
Copeptin3 0.58 (0.49–0.66) 19.8 (14.5–26.4) 78.2 (65.6–87.1) 23.8 (18.1–30.5) 73.9 (59.7–84.4)
MR-
proADM3
0.57 (0.48–0.66) 20.3 (15.0–27.0) 80.0 (67.6–88.4) 24.3 (18.6–31.1) 76.1 (62.1–86.1)
Cystatin C3 0.49 (0.41–0.58) 18.6 (13.5–25.1) 72.7 (59.8–82.7) 22.2 (16.8–28.8) 68.1 (53.8–79.6)
*For calculating the c-statistics, biomarker values were used continuous.
1 for values > 300 pg/ml
2 for values > 14 ng/L
3 for values > 20th percentile
doi:10.1371/journal.pone.0155973.t005
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Table 6. Association of biomarkers with outcomes.
PE-related complications
Crude HR (95% CI) p-value Adjusted HR* (95% CI) p-value
1 month
NT-proBNP1 1.45 (1.07 to 1.96) 0.02 1.35 (0.99 to 1.85) 0.06
hs-cTnT2 1.48 (1.22 to 1.80) <0.001 1.56 (1.26 to 1.92) <0.001
Copeptin3 1.43 (0.92 to 2.22) 0.12 1.30 (0.84 to 2.02) 0.23
MR-proADM3 1.84 (0.84 to 4.05) 0.13 1.50 (0.63 to 3.55) 0.36
Cystatin C3 0.57 (0.13 to 2.49) 0.46 0.40 (0.09 to 1.74) 0.22
3 months
NT-proBNP1 1.55 (1.18 to 2.04) 0.002 1.47 (1.11 to 1.95) 0.007
hs-cTnT2 1.45 (1.22 to 1.73) <0.001 1.52 (1.26 to 1.84) <0.001
Copeptin3 1.73 (1.16 to 2.58) 0.007 1.60 (1.08 to 2.39) 0.02
MR-proADM3 2.35 (1.23 to 4.52) 0.01 2.08 (1.03 to 4.19) 0.04
Cystatin C3 0.94 (0.28 to 3.15) 0.92 0.68 (0.20 to 2.33) 0.54
12 months
NT-proBNP1 1.40 (1.14 to 1.72) 0.001 1.38 (1.12 to 1.70) 0.003
hs-cTnT2 1.32 (1.13 to 1.54) <0.001 1.35 (1.15 to 1.58) <0.001
Copeptin3 1.38 (1.01 to 1.89) 0.04 1.35 (0.99 to 1.84) 0.06
MR-proADM3 1.71 (0.96 to 3.07) 0.07 1.61 (0.88 to 2.96) 0.13
Cystatin C3 0.81 (0.30 to 2.17) 0.68 0.68 (0.25 to 1.87) 0.46
24 months
NT-proBNP1 1.31 (1.10 to 1.56) 0.003 1.30 (1.08 to 1.56) 0.005
hs-cTnT2 1.26 (1.08 to 1.46) 0.003 1.27 (1.09 to 1.48) 0.002
Copeptin3 1.28 (0.97 to 1.68) 0.09 1.26 (0.95 to 1.66) 0.11
MR-proADM3 1.48 (0.86 to 2.56) 0.16 1.42 (0.81 to 2.51) 0.22
Cystatin C3 0.87 (0.36 to 2.10) 0.76 0.78 (0.32 to 1.91) 0.59
Biomarkers were log-transformed and used continuous. Effects (HRs) are expressed per one log-unit increase.
* adjusted for GPS
1 for values > 300 pg/ml
2 for values > 14 ng/L
3 for values > 20th percentile
doi:10.1371/journal.pone.0155973.t006
Fig 2. Cumulative incidence of PE-related complications by level of NT-proBNP (left panel) and hs-
cTnT (right panel). High versus low levels are based on pre-specified cut-offs (>300 pg/mL for NT-proBNP
and >14 ng/L for hs-cTnT).
doi:10.1371/journal.pone.0155973.g002
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follow-up period, with C-statistics ranging from 0.75 (95%CI: 0.52–0.98) to 0.79 (95% CI:
0.67–0.92) after 1 and 24 months, respectively. MR-proADM did not show significant prog-
nostic accuracy for PE-related mortality after one month (C-statistic: 0.75; 95% CI: 0.49–1.00),
but was found to be a significant predictor for PE-related morality at 24 months (C-statistic:
0.84; 95%CI: 0.70–0.97). On the other hand, cystatin C levels did not show any predictive accu-
racy at any time of follow-up for PE-related mortality with C-statistics ranging between 0.48
(95% CI: 0.16 to 0.81) and 0.61 (95% CI: 0.42 to 0.79; Table 3).
Cox-regression analyses indicated that copeptin was associated with a two-fold increased
risk of PE-related mortality at 1 month for each log-unit increase (HR: 2.39; 95%CI: 1.06–
5.36), which was no longer significant after adjusting for the PESI score (HR: 2.15; 95%CI:
0.97–4.80). MR-proADM showed a four-fold increased risk for each log-unit increase (HR:
3.54, 95% CI: 1.11–11.28) after 30 days but, as with copeptin, did not remain significant after
adjusting for the PESI score (HR: 3.13; 95%CI: 0.93–10.56). Interestingly, for copeptin and
MR-proADM, hazard ratios tended to increase gradually over time and were found to be sig-
nificantly associated with PE-related mortality after two years, independently of the PESI score
(Table 4).
Differences in the cumulative incidence of PE-related mortality by level of non-cardiac bio-
markers were not significant (Kaplan-Meier curves not shown).
Regarding the secondary endpoint, copeptin was the only non-cardiac biomarker that pre-
dicted PE-related complications at 3 months (C-statistic: 0.64; 95% CI: 0.52–0.76) and 12
months (C-statistic: 0.60; 95% CI: 0.51–0.69; Table 5). MR-proADM and cystatin C did not
show significant discriminative ability at any time during the follow-up period. Moreover,
none of the non-cardiac biomarkers (except for copeptin and MR-proADM at 3 months) dis-
played significant associations with the secondary endpoint in Cox regressions (Table 6) and
Kaplan-Meier curve analyses (graphs not shown).
Discussion
One of the major finding of this “head-to-head” comparison study is that cardiac biomarkers
appear to have better discriminant power for PE-related mortality and PE-related complica-
tions than non-cardiac biomarkers. Hs-cTnT and NT-proBNP displayed adequate discrimi-
nant power with C-statistics exceeding the benchmark value commonly set at 0.80 for cardiac
biomarkers [23]. Furthermore, for both study endpoints, NT-proBNP and hs-cTnT were in
general independently associated with the endpoints when adjusted for the PESI and GPS
scores. More interestingly, for PE-related mortality, a NT-proBNP value below 300 pg/ml had
a negative predictive value of 100% up to 24 months of follow-up, and negative predictive val-
ues above 97% up to 3 months of follow-up for PE-related complications. In general, the nega-
tive predictive values for hs-cTnT were overall very similar to those obtained for NT-proBNP.
In contrast, at the pre-specified cut-off values, both NT-proBNP and hs-cTnT displayed posi-
tive predictive values that were unsuitable, at least in the elderly population, to identify patients
who could benefit from a more aggressive treatment in a rule-in strategy. These results are in
line with the recent PEIHTO study indicating that a more aggressive management of normo-
tensive PE patients based upon cardiac troponin elevation did not translate into clear clinical
benefits [24].
Another significant contribution to the field resides in the observation that among non-
cardiac biomarkers showing some promise for PE prognosis assessment [13–15], only MR-
proADM, and copeptin appeared as valuable prognostic tools to predict PE-related mortality
in patients with non-massive PE. Indeed, for this endpoint C-statistics indicated that both MR-
proADM and copeptin had AUC values close to 0.80.
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Cox regression analyses indicated that for PE-related mortality, the association was inde-
pendent of the PESI score. The negative predictive values for PE-related mortality of these two
biomarkers appeared to be slightly lower than the ones observed for cardiac biomarkers and
we observed a substantial overlap of the 95% confidence intervals of the negative predictive val-
ues, which could be interpreted as equivalence between copeptin, MR-proADM and cardiac
biomarkers. Nevertheless, the lower limits of the 95% CI for both copeptin and MR-proADM
were lower than those of cardiac biomarkers for each time point and were below 88.7% for
both study endpoints. Accepting a negative predictive value of 88.7% would mean that for rule-
out purpose, one would accept the theoretical risk that up to 11.3% of patients deemed at low
risk would in fact die of PE-related mortality within the 1st month (and up to the third month
of treatment), which would be unacceptably high for PE patients meant to be treated in an
ambulatory setting. Along the same line of thoughts, MR-proADM and copeptin were at best
found to be marginally predictive for PE-related complications according to C-statistics, and
with the exception of copeptin and MR-proADM at 3 months, Cox regression analyses indi-
cated that the association with PE-related complication did not remain significant for both
these non-cardiac biomarkers after the adjustment for the GPS, which is the best validated
prognostic determinant in PE patients for this composite endpoint [2].
The present results partly support the results of a smaller study indicating that MR-
proADM was independently associated with increased mortality in PE patients, but do not
lend weight to its superiority to NT-proBNP [15]. Nevertheless, consistent with previous find-
ings in patients with other diseases indicating that MR-proADM could be a predictor of long-
term mortality in heart failure patients [12], we observed that the prognostic accuracy of MR-
proADM tended to increase over time, reaching C-statistics of 0.84 for PE-related mortality at
24 months, despite being a non-significant predictor at 1 month for this endpoint, or at any
time point for PE related-complications. Due to the relative low numbers of events in this
study, we cannot exclude a power issue explaining the absence of significant results for MR-
proADM for short follow-up periods. Further studies are required to confirm the long-term
prognostic value of this biomarker, as well as to define its impact on patient management. On
the other hand, cystatin C had no discriminative properties for any of the study endpoints con-
sidered. The reason why we could not reproduce the promising results reported earlier for
cystatin C [14] remains elusive. However, it could be related to the fact that only patients older
than 65 years-old were considered in this study and that age is known to have a significant
impact on MR-proADM levels [25] and on renal function.
The pathophysiological relationship between cardiac biomarkers and outcome in PE
patients might be explained by the right cardiac ventricular strain induced by vascular obstruc-
tion caused by the occluding clot [1]. Similar mechanisms could explain the association
between elevated levels of MR-proADM and outcomes in PE, as cardiomyocytes stretch and
hypoxia have been shown to promote ADM gene expression [12–13]. For copeptin, which is
supposed to be an integrative marker of endogenous stress related to any form of hemody-
namic impairment [11], the possible physiopathological link relating elevated copeptin levels
to PE outcome is less clear, but could certainly be viewed as a systemic response to impaired
haemodynamics due to RV dysfunction, correlating therefore with PE severity.
This study has several limitations. First, the limited number of patients reaching the primary
endpoint (n = 13) raises power issues, which could explain the absence of significant associa-
tions with outcomes mostly for MR-proADM and cystatin C. Therefore further larger studies
are required to confirm the superiority of cardiac over non-cardiac biomarkers for risk stratifi-
cation in non-high risk PE patients. Second, because the cut-offs for the non-cardiac biomark-
ers evaluated in this study have not been validated in PE patients, we used retrospectively
defined cut-offs arbitrarily set at the 20th and 80th percentile. As a result, additional studies are
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required to define optimal copeptin cut-offs that could be used for PE risk stratification. Never-
theless, the results from the present study mostly indicate that using the previously validated
cut-offs for hs-cTnT or NT-proBNP should be more adapted than using copeptin for risk strat-
ification purposes. Finally, we cannot formally exclude that residual confounding could have
biased the results of the present study. However, as the associations of cardiac biomarker with
risk were found to be independent of PESI and GPS scores which take into account most of
the well established prognostic determinants in PE, we consider this hypothesis as rather
unlikely, at least for cardiac biomarkers. Finally, knowing whether the present results apply to
PE patients younger than 65 years old remains to be demonstrated.
Conclusions
Although current guidelines for risk stratification of PE patient recommend the use of clinical
prediction rules, the present study indicates that in the elderly population, the use of cardiac
biomarkers could represent an adequate alternative. Given their high negative predictive value
reaching 100% for NT-proBNP for PE-related mortality and PE-related complications and the
fact that they were shown to provide incremental prognostic value over clinical scores in the
elderly population [14], cardiac biomarkers could represent valuable tools to identify low-risk
patients with PE potentially eligible for outpatient treatment. Copeptin and MR-proADM
appeared as valuable prognostic tool only for PE-related mortality prediction. On the other
hand, cystatin C does not have prognostic accuracy. The safety of cardiac biomarkers at specific
cut-off points to identify low-risk patients must be prospectively examined before their routine
use can be adopted in routine clinical care.
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